These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29225891)

  • 21. BetaMe: impact of a comprehensive digital health programme on HbA1c and weight at 12 months for people with diabetes and pre-diabetes: study protocol for a randomised controlled trial.
    Sarfati D; McLeod M; Stanley J; Signal V; Stairmand J; Krebs J; Dowell A; Leung W; Davies C; Grainger R
    Trials; 2018 Mar; 19(1):161. PubMed ID: 29506562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioural interventions for type 2 diabetes: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(21):1-45. PubMed ID: 23074526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetes Prevention and Weight Loss with a Fully Automated Behavioral Intervention by Email, Web, and Mobile Phone: A Randomized Controlled Trial Among Persons with Prediabetes.
    Block G; Azar KM; Romanelli RJ; Block TJ; Hopkins D; Carpenter HA; Dolginsky MS; Hudes ML; Palaniappan LP; Block CH
    J Med Internet Res; 2015 Oct; 17(10):e240. PubMed ID: 26499966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of a novel lifestyle intervention compared with the Diabetes Prevention Program for weight loss in adult dependents of military service members.
    Das SK; Bukhari AS; Taetzsch AG; Ernst AK; Rogers GT; Gilhooly CH; Hatch-McChesney A; Blanchard CM; Livingston KA; Silver RE; Martin E; McGraw SM; Chin MK; Vail TA; Lutz LJ; Montain SJ; Pittas AG; Lichtenstein AH; Allison DB; Dickinson S; Chen X; Saltzman E; Young AJ; Roberts SB
    Am J Clin Nutr; 2021 Oct; 114(4):1546-1559. PubMed ID: 34375387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NHS Diabetes Prevention Programme in England: formative evaluation of the programme in early phase implementation.
    Penn L; Rodrigues A; Haste A; Marques MM; Budig K; Sainsbury K; Bell R; Araújo-Soares V; White M; Summerbell C; Goyder E; Brennan A; Adamson AJ; Sniehotta FF
    BMJ Open; 2018 Feb; 8(2):e019467. PubMed ID: 29467134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight loss success in metabolic syndrome by telephone interventions: results from the SHINE Study.
    Weinstock RS; Trief PM; Cibula D; Morin PC; Delahanty LM
    J Gen Intern Med; 2013 Dec; 28(12):1620-8. PubMed ID: 23843020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
    Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
    BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial.
    Jebb SA; Ahern AL; Olson AD; Aston LM; Holzapfel C; Stoll J; Amann-Gassner U; Simpson AE; Fuller NR; Pearson S; Lau NS; Mander AP; Hauner H; Caterson ID
    Lancet; 2011 Oct; 378(9801):1485-92. PubMed ID: 21906798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study.
    Hallberg SJ; McKenzie AL; Williams PT; Bhanpuri NH; Peters AL; Campbell WW; Hazbun TL; Volk BM; McCarter JP; Phinney SD; Volek JS
    Diabetes Ther; 2018 Apr; 9(2):583-612. PubMed ID: 29417495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Report of the committee on the classification and diagnostic criteria of diabetes mellitus.
    ; Seino Y; Nanjo K; Tajima N; Kadowaki T; Kashiwagi A; Araki E; Ito C; Inagaki N; Iwamoto Y; Kasuga M; Hanafusa T; Haneda M; Ueki K
    J Diabetes Investig; 2010 Oct; 1(5):212-28. PubMed ID: 24843435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the Flexible Lifestyles Empowering Change intervention on metabolic and psychosocial outcomes in adolescents with type 1 diabetes (FLEX): a randomised controlled trial.
    Mayer-Davis EJ; Maahs DM; Seid M; Crandell J; Bishop FK; Driscoll KA; Hunter CM; Kichler JC; Standiford D; Thomas JM;
    Lancet Child Adolesc Health; 2018 Sep; 2(9):635-646. PubMed ID: 30119757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the Norfolk diabetes prevention lifestyle intervention (NDPS) on glycaemic control in screen-detected type 2 diabetes: a randomised controlled trial.
    Sampson M; Clark A; Bachmann M; Garner N; Irvine L; Howe A; Greaves C; Auckland S; Smith J; Turner J; Rea D; Rayman G; Dhatariya K; John WG; Barton G; Usher R; Ferns C; Pascale M;
    BMC Med; 2021 Aug; 19(1):183. PubMed ID: 34407811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adding web-based behavioural support to exercise referral schemes for inactive adults with chronic health conditions: the e-coachER RCT.
    Taylor AH; Taylor RS; Ingram WM; Anokye N; Dean S; Jolly K; Mutrie N; Lambert J; Yardley L; Greaves C; King J; McAdam C; Steele M; Price L; Streeter A; Charles N; Terry R; Webb D; Campbell J; Hughes L; Ainsworth B; Jones B; Jane B; Erwin J; Little P; Woolf A; Cavanagh C
    Health Technol Assess; 2020 Nov; 24(63):1-106. PubMed ID: 33243368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of supported telemetric monitoring in people with type 2 diabetes: study protocol for a randomised controlled trial.
    Wild S; Hanley J; Lewis S; McKnight J; McCloughan L; Padfield P; Paterson M; Pinnock H; McKinstry B
    Trials; 2013 Jul; 14():198. PubMed ID: 23829417
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.